Efficacy of metoclopramide for the treatment of acute migraine

Chao Jiang, MD\textsuperscript{a,b}, Ting Wang, MD\textsuperscript{c}, Zheng-guo Qiu, MD\textsuperscript{d}, Bo Chen, MB\textsuperscript{e}, Bang-jiang Fang, MD\textsuperscript{h,*}

Abstract

Background: In this study, we will assess the efficacy and safety of metoclopramide for the treatment of acute migraine (AM).

Methods: We will comprehensively search Cochrane Library, PUMBED, EMBASE, Google Scholar, Web of Science, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from the inception to July 1, 2019 to identify any eligible studies. Only randomized controlled trials will be considered for inclusion. The study selection, data collection, and management will be completed by two authors independently. The risk of bias will be assessed using Cochrane risk of bias tool. RevMan 5.3 software will be used for statistical analysis.

Results: The primary outcome includes pain intensity, as measured by visual analogue scale or others. The secondary outcomes are success rate, requirement of rescue medicine, quality of life, relapse, and adverse events.

Conclusions: This study will summarize the latest evidence for the clinical efficacy and safety of metoclopramide for the treatment of AM.

PROSPERO registration number: PROSPERO CRD42019142795.

Abbreviations: AM = acute migraine, RCTs = randomized controlled trials.

Keywords: acute migraine, efficacy, metoclopramide, randomized controlled trial, safety

1. Introduction

Acute migraine (AM) is a very common neurovascular disorder.\textsuperscript{[1,2]} It is characterized by a moderate to severe, recurrent, unilateral or bilateral, and headache which often lasts several hours to days.\textsuperscript{[3–5]} At the same time, people who experience this disorder often accompany a series of complications, such as nausea, vomiting, sensitivity to the light, sound, touch, or smell.\textsuperscript{[6–8]} Additionally, about 25% patients with AM also experience motor symptoms, transient visual or language disturbance.\textsuperscript{[9,10]} Unfortunately, its pathophysiology is still complex and insufficient understood. Therefore, if such disorder cannot be treated very well, it greatly affects health-related quality of life in patients with AM.\textsuperscript{[11,12]}

Several previous clinical studies have reported that metoclopramide can manage AM effectively.\textsuperscript{[13–23]} However, no study has assessed its efficacy and safety systematically. Thus, this study will aim to systematically evaluate the efficacy and safety of metoclopramide for the treatment of patients with AM.

2. Methods

2.1. Criteria for including studies

2.1.1. Types of studies. We will include randomized controlled trials (RCTs) of metoclopramide for AM regardless of language and publication status.

2.2. Types of interventions

The patients in the treatment group have received metoclopramide monotherapy alone.

The patients in the control group can receive any interventions, except metoclopramide.

2.3. Types of patients

Participants diagnosed with AM will be included with no limitation of race, gender, and economic status.

2.4. Types of outcome measurements

The primary outcome includes pain intensity, as measured by visual analogue scale or others. The secondary outcomes are success rate, requirement of rescue medicine, quality of life (it can...
be assessed by The Short Form-36 Health Survey or any relevant scales), relapse, and adverse events.

2.5. Search strategy

We will comprehensively search the following electronic databases from inception to the July 1, 2019: Cochrane Library, PUMBED, EMBASE, Google Scholar, Web of Science, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. No language or publication date is limited. The sample of search strategy for Cochrane Library is shown in Table 1. Similar search strategies for other electronic databases will also be built.

In addition, any clinical registry, conference proceedings, reference lists of identified relevant RCTs, comments, and reviews will also be searched to identify any planned, ongoing, or unpublished literature.

2.6. Data collection and analysis

2.6.1. Study selection. The study selection will be completed by two authors independently. They will check all literature results each other. When any divergences occur, a third independent author will help to make the final decision by discussion. Full texts of all remaining potential studies will be read if it is necessary. Details of whole study selection process will be presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart in Figure 1.

2.6.2. Data extraction. A piloted data extraction form has been built by all authors. The following information will be collected from all eligible studies independently by two authors: general information of each included study, patient characteristics, study...
population, study setting, study methods, treatment details, outcome measurements, safety, and any others. Any different opinions will be resolved by discussion with the help of a third independent author.

2.6.3. Missing data dealing with. If the data is unclear, missing or presented in the form that cannot be collected, we will attempt to contact primary authors by email to obtain those data if it is possible. If we cannot obtain those data from original authors, we will analyze available data only.

2.6.4. Risk of bias assessment. Two authors will independently evaluate the risk of bias using Cochrane risk of bias tool. This tool comprises of 7 domains, and each one is further graded as high, low, or unclear risk of bias according to the relevant information extracted from each included study. Any different opinions will be solved by consensus with a third independent author.

2.6.5. Methods of treatment measurements. For dichotomous data, risk ratio and 95% confidence intervals will be presented. For continuous data, mean difference or standardized mean difference, and 95% confidence intervals will be calculated.

2.6.6. Assessment of heterogeneity. The heterogeneity among included studies will be tested by the I² statistics. If the value of I² is ≤50%, the heterogeneity will be minor, and a fixed-effect model will be applied. Otherwise, if the value of I² is > 50%, the heterogeneity across studies will be statistically substantial, and a random-effect model will be used.

2.6.7. Assessment of reporting bias. We will check publication bias using funnel plot and Egger’s regression test if >10 RCTs are included.[24,25]

2.7. Data synthesis

RevMan 5.3 software will be applied for statistical analysis. If the heterogeneity is minor (I² ≤ 50%), we will apply a fixed-effect model for data pooling, and meta-analysis will be carried out. Otherwise, if the heterogeneity is substantial (I² > 50%), we will use a random-effect model to pool the data, and subgroup analysis will be performed. A narrative description of the outcome results will be conducted when the meta-analysis is still not feasible after subgroup analysis.

2.7.1. Subgroup analysis. We will carry out subgroup analysis to identify any possible causes of substantial heterogeneity if it is necessary. It will be carried out based on the type of treatments, comparators, and outcome measurements.

2.7.2. Sensitivity analysis. We will perform sensitivity analysis to test the stability and robustness of pooled treatment effects by removing low quality studies.

3. Discussion

Metoclopramide may be used for the treatment of patients with AM. However, no study on this topic has been reported systematically. This study will summarize more convincing information on metoclopramide for the treatment of AM. In addition, its results will also provide information on the credibility current evidence and research directions for both clinical practice and further studies.

3.1. Ethics and dissemination

This study will not involve personal patient information, thus, no ethical approval will be required. The results of this study will be published in a peer-reviewed journal.

Acknowledgment

The supporters had no role in this study.

Author contributions

Conceptualization: Chao Jiang, Ting Wang, Bo Chen, Bang-jiang Fang.
Data curation: Chao Jiang, Zheng-guo Qiu, Bo Chen, Bang-jiang Fang.
Formal analysis: Chao Jiang, Ting Wang, Zheng-guo Qiu.
Funding acquisition: Bang-jiang Fang.
Investigation: Chao Jiang, Bang-jiang Fang.
Methodology: Chao Jiang, Ting Wang, Zheng-guo Qiu, Bo Chen.
Project administration: Bang-jiang Fang.
Resources: Chao Jiang, Ting Wang, Zheng-guo Qiu, Bo Chen, Bang-jiang Fang.
Software: Ting Wang, Zheng-guo Qiu, Bo Chen.
Supervision: Bang-jiang Fang.
Validation: Chao Jiang, Ting Wang, Bo Chen, Bang-jiang Fang.
Visualization: Chao Jiang, Zheng-guo Qiu, Bang-jiang Fang.
Writing – review & editing: Chao Jiang, Ting Wang, Zheng-guo Qiu, Bo Chen, Bang-jiang Fang.

References

[1] Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med 2002;39:215–22.
[2] Friedman BW, Hochberg ML, Esses D, et al. Applying the International Classification of Headache Disorders to the emergency department: an assessment of reproducibility and the frequency with which a unique diagnosis can be assigned to every acute headache presentation. Ann Emerg Med 2007;49:409–19.
[3] Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–57.
[4] Met A, Tielt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008;21:331-7.
[5] Becker WJ. Acute Migraine Treatment. Continuum (Minneap Minn) 2015;21:953–72.
[6] Charles A. Migraine. N Engl J Med 2017;377:553–61.
[7] Aukerman G, Knutson D, Miser WF, et al. Management of the acute migraine headache. Am Fam Physician 2002;66:2123–30.
[8] Valade D. Early treatment of acute migraine: new evidence of benefits. Cephalalgia 2009;29(Suppl 3):15–21.
[9] Headache Classification Committee of the International Headache Society-Part one—the primary headaches. Cephalalgia 2004;24(Suppl 1):23–136.
[10] Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med 2002;346:257–70.
[11] Lainez MJ, Lopez A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache 2005;45:883–90.
[12] Lantéri-Minet M, Radat F, Chautard MH, et al. Anxiety and depression associated with migraine: influence on migraine subjects’ disability and quality of life, and acute migraine management. Pain 2005;118:319–26.
[13] Le Jeune C, Gómez JP, Pradalier A, et al. Comparative efficacy and safety of calcium carbamazepate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Eur Neurol 1999;41:37–43.
[14] Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache 1995;35:236–9.

[15] Shahrami A, Assarzadegan F, Hatamabadi HR, et al. Comparison of therapeutic effects of magnesium sulfate vs. dexamethasone/metoclopramide on alleviating acute migraine headache. J Emerg Med 2015;48:69–76.

[16] Hakkarainen H, Allonen H. Ergotamine vs. metoclopramide vs. their combination in acute migraine attacks. Headache 1982;22:10–2.

[17] Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Ann J Emerg Med 1996;14:262–4.

[18] Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995;2:597–602.

[19] Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med 2011;57:475–82.

[20] Gaffigan ME, Bruner DI, Wason C, et al. A randomized controlled trial of intravenous haloperidol vs. intravenous metoclopramide for acute migraine therapy in the Emergency Department. J Emerg Med 2015;49:326–34.

[21] Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med 2008;52:399–406.

[22] Cete Y, Dora B, Ertan C, et al. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 2005;25:199–204.

[23] Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology 2014;82:976–83.

[24] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.

[25] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.